Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Abstract Objective To estimate the relationship between serum TNFα, IL-6, and serum CZP levels and the clinical response to CZP in RA patients in the TSUBAME study. Methods One hundred patients with RA who received CZP were enrolled and multiple clinical parameters, serum TNFα, IL-6, and CZP levels,...

Full description

Bibliographic Details
Main Authors: Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Kazuyoshi Saito, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Biological therapies
DMARDs
Pharmacology
Biomarkers
Online Access:https://doi.org/10.1186/s13075-021-02547-2

Internet

https://doi.org/10.1186/s13075-021-02547-2

Similar Items